fda glp-1 compounding warning letters september 2025 Sends 30 To Continue Clampdown on Compounded GLP-1s FDA issued 25 warning letters

Importantly, impressive weight reductions of 8% were observed after only 28 days, without any participant dropout due to GI side effects

A critical evaluation of crizanlizumab for the treatment of sickle cell disease

Toward More Tailored Dosing Strategies While the panacea of individualised dosing regimens might represent a leap too far in terms of complexity, the opportunity does exist for pharmaceutical companies to implement a more tailored approach when it comes to dosing, arriving at a more delicate balance of drug exposure, bioavailability, efficacy and safety based on the characteristics of certain patient cohorts

Can peptides help with body recomposition, not just muscle gain